Therapeutic Class

Dyslipidaemic Agents


Corpid used complementary to diet to reduce total cholesterol, LDL- cholesterol, apo - B and triglycerides in humans increased cholesterol/ blood with primary (heterozygous type with orwithout the family) and lipid disturbances I blood mixture (the Fredrickson type IIa and llb). Atorvastatin is also indicated complementary to diet to treat the increased concentrations of triglyceride I serum (Fredrickson Type IV).As indicated for the treatment of beta - lipoprotein Iblood disorder (Fredrickson Type III)that do not meet full nutrition, also used to lower cholesterol I blood homozygous familial character, such as supplements for other drugs to reduce lipid group Iblood or when the drug was not effective.

Chemical Composition

Atorvastatin 10 mg


1 x 10's/ Box

Dosage & Administration

The starting dose is I 0 mg daily. Daily dose range is 10- 80mg, used 1time / day Infants after breastfeeding : drug information for this object has not been established.


Hypersensitivity to drug ingredients. Advanced liver disease or when there is increased transaminase I serum persistent , unexplainable and triple the highest normal level.

Side Effects

Atorvastatin tolerated. These adverse reactions may experience constipation, heartburn, anorexia, abdominal pain, headache, nausea, musclepain,diarrhea,fatigue,insomnia. *Inform to physicianif any unwanted effects occur during drug*

Drug Interaction

Antacid: When atorvastatin combi nes with an antacid suspension, the plasma concentrations of atorvastatin decreased approximately 35% Colestipol: Coordinate colestipol with atorvastatin reduces the concentration of atorvastatin Iplasma is about 25%. Digoxin: When multiple doses of atorvastatin is taken with digoxin, the stable digoxin concentration Iplasma will be increased 20% Erythromycin: In healthy peopl e, oral erythromycin with atorvastatin will make the concentrations of atorvastatin I plasma increased 40% Oral contraceptiv es: the combination of atorvastatin with oral contraceptives, the value of the area under the curve (AUC) of norethindrone and ethinyl estradiol will increase in the order of 30% and20%